TABLE 2 | Promising investigational antiretroviral drugs, 2007*
From the following article:
HIV drug development: the next 25 years
Charles Flexner
Nature Reviews Drug Discovery 6, 959-966 (December 2007)
doi:10.1038/nrd2336
| Name | Target | Company | Phase |
|---|---|---|---|
| Raltegravir | HIV integrase | Merck | Preregistration |
| Elvitegravir | HIV integrase | Japan Tobacco, Gilead | II |
| Vicriviroc | CCR5 chemokine co-receptor | Schering–Plough | III |
| INCB009471 | CCR5 chemokine co-receptor | Incyte Corporation | II |
| AMD-070 | CXCR4 chemokine co-receptor | AnorMED | II |
| Bevirimat | Polyprotein maturation | Panacos Pharmaceuticals | II |
| Amdoxovir | NRTI | RFS Pharma | II |
| Apricitabine | NRTI | Avexa | II |
| Racivir | NRTI | Pharmasset | II |
| Reverset | NRTI | Incyte | Discontinued‡ |
| Etravirine | NNRTI | Tibotec | Preregistration |
| Rilpivirine | NNRTI | Tibotec | III |
| UK-453,061 | NNRTI | Pfizer | II |
| Brecanavir | HIV protease inhibitor | GlaxoSmithKline | Discontinued§ |
| *Table includes oral agents producing a >0.5 log mean decrease in HIV plasma RNA concentration when given for a minimum of 10 days to infected patients; in the case of AMD-070, this standard applies to concentrations of chemokine (C-X-C motif) receptor 4 (CXCR4)-tropic virus only.‡In 2006 owing to increases in grade 4 hyperlipasemia in patients receiving reverset.§In 2006 owing to formulation issues. CCR5, chemokine (C-C motif) receptor 5; NNRTI, non-nucleoside reverse-transcriptase inhibitor; NRTI, nuceloside or nucleotide reverse-transcriptase inhibitor. | |||
Download file
If the slide opens in your browser, select "File > Save As" to save it.